How effective is Darolutamide in treating prostate cancer?

Darolutamide tablets (Darolutamide) is a new androgen receptor inhibitor that has shown significant clinical efficacy in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). According to the results of the global multi-center III phase ARAMIS trial, darotamide combined with androgen deprivation therapy (ADT) can significantly prolong metastasis-free survival (MFS), the median metastasis-free survival reached 40 months, while the placebo group was only 18.4 months, and the risk of disease metastasis or death was reduced by 59%.

Long-term follow-up data show that darotamide can not only delay the progression of prostate cancer, but also improve the overall survival of patients. In the final analysis of the ARAMIS study, the median overall survival in the darolutamide group was significantly better than that in the control group, and the risk of death was reduced by 31%. This makes darolutamide the first drug to have outstanding performance in prolonging both metastasis-free survival and overall survival among nmCRPC patients, and its efficacy has been widely recognized internationally.

Compared with similar drugs such as enzalutamide and apalutamide, darotamide has better safety and tolerability. Its ability to penetrate the blood-brain barrier is lower, resulting in a lower incidence of central nervous system-related side effects (e.g., fatigue, seizures, mood changes). In clinical trials, most patients can adhere to treatment for a long time, and adverse reactions are mostly mild to moderate, which is crucial to sustaining the efficacy.

Darotamide also shows promising therapeutic potential in the population with metastatic hormone-sensitive prostate cancer (mHSPC). The ARASENS study showed that darolutamide combined with ADT and docetaxel chemotherapy significantly reduced the risk of death by 32% and improved multiple secondary endpoints such as time to disease progression and time to first symptom worsening. This indicates that darolutamide has efficacy advantages in a broader population of prostate cancer and is expected to become a key drug in multi-stage treatment regimens in the future.

Reference materials:https://www.fda.gov/drugs/